Evidence & regulatory context
- Mechanism
- Experimental genetic knockdown or knockout of gastrokine 2 (GKN2, blottin), a stomach-restricted secreted BRICHOS-domain protein that heterodimerises with trefoil factor 1 (TFF1). This is a genetic manipulation rather than a therapeutic agent, so no ChEMBL entity exists and no drug-like modulator has been developed.
- Target
- Not recorded
- Injury models
- Other
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseOtherC57BL/6 and transgenic miceMale and female
Model: Water immersion restraint stress-induced acute gastric lesions
GKN2 aggravated stress-induced gastric lesions and mucosal cell death in a gastric acid independent manner by recruiting neutrophils and driving inflammatory factor release through the NLRP3 inflammasome, so inhibiting GKN2 attenuated the lesions. Cortisol-activated NR3C1 acted as the upstream tran…
Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.
